中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

35 records (took 0.021 seconds)

    Pharmaceutical compositions comprising monoterpenes
    21.
    发明授权
    Pharmaceutical compositions comprising monoterpenes 有权

    公开(公告)号：US10899691B2

    公开(公告)日：2021-01-26

    申请号：US16575587

    申请日：2019-09-19

    Applicant: NEONC Technologies, Inc.

    Inventor： Thomas Chen ,  Daniel Levin ,  Satish Puppalli

    IPC: C07C29/92 ,  C07C67/14 ,  C07C201/12 ,  A61K31/045 ,  C07C29/78 ,  C07C29/88 ,  C07C201/16 ,  A61K31/4188 ,  A61K45/06 ,  A61N5/10 ,  C07C29/86

    Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

    METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVE
    27.
    发明申请
    METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVE 有权
    使用包含百里香醇衍生物的组合物治疗癌症的方法

    公开(公告)号：US20160243114A1

    公开(公告)日：2016-08-25

    申请号：US15026649

    申请日：2014-10-08

    Applicant: NEONC TECHNOLOGIES INC.

    Inventor： Thomas Chen

    IPC: A61K31/495 ,  A61K31/045 ,  A61K45/06 ,  A61K47/48

    CPC classification number: A61K31/495 ,  A61K9/0043 ,  A61K9/0085 ,  A61K47/54 ,  A61K47/55

    Abstract: A method for treating brain metastases of a cancer in a mammal includes administering to the mammal a therapeutically effective amount of a perillyl alcohol carbamate, such as TMZ−POH. The brain metastases can be originated or spread from breast cancer. The penllyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent, such as a chemotherapeutic agent. The chemotherapeutic agents that may be used in the present invention include a DNA alkylating agent, a topoisomerase inhibitor, an endoplasmic reticulum stress inducing agent, a platinum compound, an antimetabolite, an enzyme inhibitor, and a receptor antagonist.

    Abstract translation: 用于治疗哺乳动物的癌症的脑转移的方法包括向哺乳动物施用治疗有效量的诸如TMZ-POH的硫酸氨基甲酸酯。 脑转移可以起源于或从乳腺癌扩散。 噻吩醇衍生物可以是与治疗剂缀合的香叶醇，例如化学治疗剂。 可用于本发明的化学治疗剂包括DNA烷化剂，拓扑异构酶抑制剂，内质网应激诱导剂，铂化合物，抗代谢物，酶抑制剂和受体拮抗剂。

    Pharmaceutical compositions comprising monoterpenes
    30.
    发明授权
    Pharmaceutical compositions comprising monoterpenes 有权

    公开(公告)号：US10457618B2

    公开(公告)日：2019-10-29

    申请号：US15220135

    申请日：2016-07-26

    Applicant: NEONC Technologies, Inc.

    Inventor： Thomas Chen ,  Daniel Levin ,  Satish Puppali

    IPC: C07C29/92 ,  A61K31/045 ,  C07C67/14 ,  C07C201/12 ,  C07C29/78 ,  C07C29/88 ,  C07C201/16 ,  A61K31/4188 ,  A61K45/06 ,  A61N5/10 ,  C07C29/86

    Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

Patent Agency Ranking